They identified the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) as an enhancer of GRN expression and validated their results in cells from patients with frontotemporal dementia (Cenik et al., 2011). The gene discussed is GRN; the disease is frontotemporal dementia.